Photo of Deniz Can Guven/X
May 18, 2024, 06:04
Deniz Can Guven: The 1st-in-human phase 1 study on arginase inhibitor INCB001158
Deniz Can Guven, Medical Oncologist at , shared on X/Twitter:
”The 1st-in-human phase 1 study on arginase inhibitor INCB001158 is out on BMJ Oncology.
Led by my great mentor Aung Naing.
Tested a strong preclinical hypothesis:
- A total of 107 patients.
- Monotherapy or with pembrolizumab.
- + Tolerable with fatigue and GI adverse events.
- – Very limited efficacy.
Need more data on the role of arginine metabolism in TME immunosuppression. Kudos to all authors.”
Read further.
Source: Deniz Can Guven/X
Aung Naing
BMJ Oncology
cancer
Deniz Can Guven
Elena Garralda
Emil Kuriakose
Glenn J. Hanna
Health Sciences University
Howard Kallender
immunotherapy
Kyriakos P Papadopoulos
LuLu Cheng
Michael J Pishvaian
Michael Smith
Mike Pishvaian
Omar Saavedra
OncoDaily
Oncology
Osama Rahma
pembrolizumab
Sven Gogov
TME immunosuppression
Todd Bauer
Xuejun Chen